## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden					
ours per response					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	es)													
Name and Address of Reporting Person * McWherter Charles				2. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BOULEVARD, SUITE 130				3. Date of Earliest Transaction (Month/Day/Year) 11/02/2017							X Officer (give title below) Other (specify below)  SVP & Chief Scientific Officer				
(Street) NEWARK, CA 94560			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person							
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	ecurity	D	2. Transaction Date (Month/Day/Year)	•	if Coo (Ins	Code (Instr. 8)		(A) or Disposed of ( (Instr. 3, 4 and 5)		of (D)			Following (s)	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial
				(Month/Day/Ye		Code	V	Amoun	(A) or (D)	Price	(Instr. 3 a	ina 4)		· /	Ownership (Instr. 4)
Common	Stock		11/02/2017			P		300	ΙΔ	\$ 8.67	10,300			D	
Common	Stock		11/02/2017			P		4,700	A	\$ 8.668	15,000			D	
Reminder: I	Report on a	separate line f	for each class of secu	urities beneficial	ly owne	d dire	etly o	r							
							cont	ained i	n this fo	orm are	e not req	ction of in uired to re d OMB cor	spond unl	ess	EC 1474 (9- 02)
				Derivative Secur							lly Owned	I			
	2. Conversion or Exercise Price of Derivative Security		Year) Execution Da	4. Transactic Code Year) (Instr. 8)	on of Deri Secu Acq (A) Disp of (I (Inst	of a		6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Und Secu	itle and bunt of erlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	(Instr. 4)
				Code	V (A)	(D)	Date Exe	e rcisable	Expiration Date	on Title	Amount or Number of Shares				
Repor	ting O	wners													

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
McWherter Charles C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BOULEVARD, SUITE 130 NEWARK, CA 94560			SVP & Chief Scientific Officer				

# **Signatures**

/s/ Sujal Shah, Attorney-in-Fact for Charles A. McWherter	11/06/2017
Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.